Abstract
Because CsA is subject to extensive hepatic metabolism (1), the possibility of pharmacokinetic drug interaction can be anticipated if drugs which enhance or inhibit its metabolism are co-administered (2–4). In addition to this, there is the possibility of interaction if other drugs given with CsA are nephrotoxic, since they may enhance the toxicity of CsA (5).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maurer, G., Loosli, H.R., Schreiner, E. and Keller, B. Drug Metab. Disp. 24: 120–126, 1984.
Gumbleton, M., Brown, J.E., Hawksworth, G. and Whiting, P.H Transplantation 40: 454–455, 1985.
Griñó, J.M., Sabater, I., Castelao, A.M., Guardia, M. and Serón, D. Ann. Intern. Med. 105: 467–468, 1986.
Griñó, J.M., Sabater, I., Castelao, A.M. and Alsina, J. Lancet 1: 1387, 1986.
Bennet, W. Clin. Nephrol. 25: 126–129, 1986.
Jhonson, P.C., Kumor, K., Welsh, M.S., Woo, J. and Kahan, B. D. Transplantation 44: 329–331, 1987.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Castelao, A.M. et al. (1989). Cyclosporin A (CSA) Drug Interactions. In: Andreucci, V.E., Dal Canton, A. (eds) Current Therapy in Nephrology. Developments in Nephrology, vol 24. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0865-2_139
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0865-2_139
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8209-9
Online ISBN: 978-1-4613-0865-2
eBook Packages: Springer Book Archive